Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
JOHNSON ELEC H
00179
5
HORIZONROBOT-W
09660
HK Stock MarketDetailed Quotes
DUALITYBIO-B (09606)
- 273.800
- -1.200-0.44%
Trading Jul 8 10:51 CST
24.10BMarket Cap-21.25P/E (TTM)
283.000High270.200Low50.75KVolume270.200Open275.000Prev Close14.07MTurnover0.06%Turnover RatioLossP/E (Static)88.04MShares289.80052wk High-11.04P/B24.10BFloat Cap165.50052wk Low--Dividend TTM88.04MShs Float289.800Historical High--Dividend LFY4.66%Amplitude165.500Historical Low277.202Avg Price100Lot Size--Div Yield TTM--Div Yield LFY
About DUALITYBIO-B Company
Yingen Biotech is an innovative clinical-stage biopharmaceutical company focused on developing next-generation antibody-conjugated drugs (ADCs) for patients with cancer and autoimmune diseases. The company has successfully built several next-generation ADC technology platforms with global intellectual property rights. Based on in-depth research and exploration of the biological mechanisms of diseases, Yingen Biotech has a rich clinical ADC research and development pipeline, and has carried out multiple global multi-center clinical trials in more than 17 countries, enrolling more than 2,000 patients. At the same time, Yingen Biotech has reached a number of overseas licensing agreements with global pharmaceutical companies and top innovative pharmaceutical companies. As a global ADC innovation engine, Yingen Biotech continues to develop the next generation of novel ADCs, including dual-antibody ADCs, novel mechanism-loaded ADCs, and self-exempt ADCs.
Company Profile
Symbol09606
Company NameDUALITYBIO-B
ISINKYG2929M1087
Listing DateApr 15, 2025
Issue Price94.60
Shares Offered17.33M share(s)
FoundedJul 3, 2019
Registered AddressCayman Islands
Chairmanzhongyuan zhu
Secretaryjialicengyingwen yuan
Audit InstitutionPricewaterhouseCoopers
Company CategoryOverseas registration of Mainland Individuals control
Registered Office4th Floor, Harbour Place 103 South Church Street George Town P.O. Box 10240 Grand Cayman KY1-1002 Cayman Islands
Head Office and Principal Place of Business40th Floor, Dah Sing Finance Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees170
MarketHong Kong motherboard
Phone(021)26018730
EmailIR@dualitybiologics.com;info@dualitybiologics.com
Business Yingen Biotech is an investment holding company mainly engaged in clinical-stage biopharmaceuticals. The company is dedicated to developing innovative antibody-conjugated drugs (ADCs) for patients with cancer and autoimmune diseases. The company's main drug candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419, and DB-2304. The company's products are mainly used to target endometrial cancer (EC), breast cancer (BC), small cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), and head and neck squamous cell carcinoma (HNSCC). The company mainly operates in domestic and foreign markets.
Company Executives
- Name
- Position
- Salary
- zhongyuan zhu
- Chairman of the Board, CEOs, Executive Director, Chairman of the Nomination Committee, Originators, Authorized Representative
- --
- shaoren zhang
- Executive Director, Vice President of Finance
- --
- wen si
- Executive Director, Executive Director of Human Resources, Remuneration Committee Members
- --
- zhiyang cai
- Non-executive Directors
- --
- tao yu
- Non-executive Directors
- --
- QIU Yang
- Chief Scientific Officer
- --
- dong xie
- Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members
- --
- hua mou
- Global Chief Medical Officer
- --
- fengyong gao
- Independent Non-Executive Director, Remuneration Committee Members, Audit Committee Members
- --
- shuyin chuai
- Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
- --
- wei gu
- Chief Medical Officer
- --
- WANG Xin
- Chief Commercial Officer
- --
- haiqing hua
- Senior Vice President, Head of Drug Discovery
- --
- xin yu
- Vice President and Head of Regulatory Affairs
- --
- SHI Rong
- Vice President of Development Sciences
- --
- CHU Ruiyin
- Vice President of Translational Medicine
- --
- lan zhou
- Vice President of Business Global Strategy
- --
- jiali yuan
- Legal and Compliance Officer, Joint Company Secretary
- --
- yingwen ceng
- Joint Company Secretary, Authorized Representative
- --
Market Insights
Robotics Investment Opportunities Robotics Investment Opportunities
Robotics includes companies involved in the design, creation, and manufacture of robots. These machines can perform tasks autonomously or semi-autonomously, often with the aim of improving efficiency, productivity, and safety across various industries.
Robotics companies are rapidly innovating new technology with applications across many industries. They offer opportunities for growth and efficiency, align with long-term automation trends, and have the potential for disruption in emerging markets, making them appealing to investors. Robotics includes companies involved in the design, creation, and manufacture of robots. These machines can perform tasks autonomously or semi-autonomously, often with the aim of improving efficiency, productivity, and safety across various industries.
Robotics companies are rapidly innovating new technology with applications across many industries. They offer opportunities for growth and efficiency, align with long-term automation trends, and have the potential for disruption in emerging markets, making them appealing to investors.
Unlock Now
Discussing
The tariff deferral period has been extended! How have trade policies in various countries evolved?
On the 7th local time, U.S. President Trump signed an executive order extending the so-called "reciprocal tariff" delay period, postponing t
Food流油
Apr 14 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"